RecruitingNot ApplicableNCT02813642
Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients
Evaluation of Non Traditional Cardiovascular Risk Factors in Chronic Kidney Disease Patients Starting Dialysis
Sponsor
University Hospital, Montpellier
Enrollment
400 participants
Start Date
Dec 8, 2011
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the relationships between bone mineral markers levels at dialysis start and vascular calcification progression during a 2 year follow up
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria2
- Patient who has signed the written consent form
- Patient with chronic renal failure starting dialysis therapy
Exclusion Criteria2
- Pregnancy
- Patient with chronic renal failure not yet on dialysis therapy
Interventions
BIOLOGICALPlasma osteoprotegerin level
dosage of plasma osteoprotegerin
BIOLOGICALPlasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
PROCEDUREVascular calcification score
measurement of vascular calcification score by X-ray of the lateral abdominal aorta
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02813642
Related Trials
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945102 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT06926660153 locations
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283178 locations
A Prospecitve Multicenter, Observational Registry Study
NCT074815261 location